Matches in UGent Biblio for { <https://biblio.ugent.be/publication/526259#aggregation> ?p ?o. }
Showing items 1 to 27 of
27
with 100 items per page.
- aggregation classification "D1".
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 526259.bibtex.
- aggregation hasFormat 526259.csv.
- aggregation hasFormat 526259.dc.
- aggregation hasFormat 526259.didl.
- aggregation hasFormat 526259.doc.
- aggregation hasFormat 526259.json.
- aggregation hasFormat 526259.mets.
- aggregation hasFormat 526259.mods.
- aggregation hasFormat 526259.rdf.
- aggregation hasFormat 526259.ris.
- aggregation hasFormat 526259.txt.
- aggregation hasFormat 526259.xls.
- aggregation hasFormat 526259.yaml.
- aggregation language "eng".
- aggregation publisher "".
- aggregation rights "I don't know the status of the copyright for this publication".
- aggregation subject "Biology and Life Sciences".
- aggregation title "Studying the therapeutic benefit of a glucocorticoid receptor phytomodulator in synoviocytes derived from rheumatoid arthritis patients".
- aggregation abstract "Rheumatoid arthritis (RA) is a chronic inflammatory ailment that is characterized by the hyperproliferative and invasive nature of fibroblast-like synoviocytes (FLS). Although research is advancing and therapies have greatly improved over the past years, current treatment regimens still suffer major drawbacks. This is unfortunately also the case for glucocorticoids (GCs), the most important and frequently used class of inflammatory drugs. Indeed, the usage of glucocorticoids (GCs) is overshadowed not only by the occurrence of severe side effects, such as osteoporosis, but also by the occurrence of resistance to the therapeutic effects of GCs, thereby limiting the treatment options of patients with RA. The main goal of GC/glucocorticoid receptor (GR) research thus remains to find new GR modulators that provide the same anti-inflammatory power, yet with reduced toxicity. A milestone in the history of identifying new, improved glucocorticoid receptor (GR) ligands, coincided with the recognition that activation (metabolic/unwanted effects) and repression (anti-inflammatory effects) of gene expression by GR could be addressed separately. Consequently, the objectives of this thesis were to unravel the therapeutic potential of Compound A (CpdA), a dissociative GR modulator, for the treatment of RA. In addition, it was questioned whether the anti-inflammatory effect of CpdA is associated with an improved side effect profile in comparison with currently available synthetic GCs, using the strong GR agonist dexamethasone (DEX) as a paradigm. In this work, the possible advantage of CpdA over DEX with regard to glucocorticoid-induced osteoporosis (GIO) and acquired resistance to the therapeutic effects of GCs was brought into special focus. As it is well known that cell lines and primary cells differ in their response to pro-inflammatory cytokines, a particularly important aspect of this research was the use of fibroblasts, isolated from the inflamed synovium of RA-patients, as a physiologically relevant ex vivo cell system to be able to unravel the molecular mechanisms by which CpdA exerts its effects.".
- aggregation authorList BK1450163.
- aggregation aggregates 4334937.
- aggregation isDescribedBy 526259.
- aggregation similarTo LU-526259.